Search Results 641-650 of 15423 for Aspergillosis

  1. A Study to Evaluate Itacitinib for Low Risk Graft-vs-Host Disease (GVHD) - Mayo Clinic

    Itacitinib is an experimental drug with an excellent safety record and appears to have activity as a GVHD treatment. A new blood test can identify patients ...

  2. Science Saturday: Sleuthing out the fingerprint of disease - Mayo Clinic News Network

    In the winter of 2014, staff of the Newborn Intensive Care Unit had a serious problem. Researchers at Mayo Clinic Hospital — Rochester, Saint Marys Campus ...

  3. Selected Publications - Mayo Clinic Research

    Review selected publications from Dr. Pang's Computer-Aided Molecular Design Lab at Mayo Clinic's campus in Minnesota.

  4. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  5. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  6. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  8. Kevin C. Halling, M.D., Ph.D. - Mayo Clinic Faculty Profiles

    D., is in developing RNA-based tests such as RNA sequencing (RNA-seq) and NanoString to increase understanding of the molecular basis of various tumor types and ...

  9. Antimicrobial Stewardship - Overview - Mayo Clinic

    Learn about the proper use of medicines used to treat infections caused by bacteria, fungi and viruses, an area of medicine called antimicrobial ...

  10. DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) - Mayo Clinic

    The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.